- Two new Executive Board members appointed under recently
announced interim CEO, Hervé Brailly
- Yannis Morel broadens remit to Chief Operating
Officer
- Sonia Quaratino, Chief Medical Officer, appointed to the
Executive Board
- Arvind Sood joins the Company and is appointed Executive
Vice President, President of US Operations and to the Executive
Board
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that it
has strengthened the Company’s leadership and corporate governance
with the appointment of two new Executive Board members. Arvind
Sood, Executive Vice President (EVP), President of US Operations,
Dr Sonia Quaratino, EVP, Chief Medical Officer are thus joining
Hervé Brailly, interim Chief Executive Officer and Yannis Morel,
EVP, Chief Operating Officer.
Yannis Morel, current EVP, Business Development and Product
Portfolio Strategy and member of the Executive Board broadens his
remit to become EVP, Chief Operating Officer extending his
operational responsibility to the management of research and early
development, working with Innate Pharma Chief Scientific Officer
Prof. Eric Vivier, and Chief Development Officer, Nicola
Beltraminelli.
Dr. Sonia Quaratino, current EVP, Chief Medical Officer is
appointed to the Executive Board. Dr. Quaratino joined Innate
Pharma in October 2023 bringing over 25 years of experience in
basic research, clinical development, and translational medicine,
having worked in academia, global large pharmaceuticals, and
biotech companies.
Arvind Sood joins the Company in a newly created position of
Executive Vice President, Innate Pharma SA and President of US
Operations. Arvind is also appointed to the Executive Board. Based
in the United States, Arvind will be responsible for the execution
of the Company’s US strategy, helping expand the Company’s US
investor base, and sourcing of business development and corporate
development opportunities in the US including liaising with
academic institutions and clinical key opinion leaders. Arvind
joins Innate Pharma most recently from Amgen and has amassed over
four decades of experience within large biopharma companies in
areas including commercial operations, investor relations and
financial communications.
As previously announced, Hervé Brailly is acting as interim CEO
and Chairman of the Executive Board since January 1st, 2024, while
a permanent successor is sought. Mr. Brailly was previously, Innate
Pharma’s Chairman of the Supervisory Board. He is a co-founder of
the Company and was CEO until December 2016.
“We are taking steps to position Innate Pharma for future
success by significantly strengthening our Executive Board now
comprising Yannis, Sonia and Arvind,” said Hervé Brailly,
interim Chief Executive Officer. “Building relationships in the
US is a core part of our strategy, and I am delighted to welcome
Arvind, who has demonstrated his ability to work effectively in
global enterprises and building strong relationships with the
global investment community. Together with the rest of the
leadership team, I am looking forward to working with Arvind to
execute on our strategy as we expand our footprint in the US
market.”
“I am excited by Innate’s proprietary platform for developing
multi-specific NK (natural killer) cell engagers, which has the
potential to drive the next wave of innovation in cancer
immunotherapy,” said Arvind Sood, President of US
Operations. “Innate is advancing a robust pipeline of drug
candidates and I am looking forward to working with the entire
leadership team to further strengthen Innate’s business and
contribute to its strategy of bringing these important potential
treatments to patients.”
Arvind joins Innate Pharma from Amgen where he most recently
served as vice president, Investor Relations. Prior to Amgen,
Arvind served as senior vice president, Investor Relations and
Financial Communications at Aventis S.A. (now Sanofi), based in
Paris, France. Arvind also worked at the Upjohn Company (now
Pfizer) of Kalamazoo, Michigan, where he served in several
functions including pharmaceutical sales, marketing and investor
relations. He obtained his undergraduate degree in Business
Administration from Western Michigan University and his master's
degree in Business Administration from Central Michigan
University.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code Ticker code
LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103077864/en/
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (EU:IPH)
Historical Stock Chart
From Apr 2024 to May 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
From May 2023 to May 2024